Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Cash Flow: 2010-2024

Historic Net Cash Flow for Whitehawk Therapeutics (WHWK) over the last 14 years, with Dec 2024 value amounting to -$34.2 million.

  • Whitehawk Therapeutics' Net Cash Flow fell 909.29% to -$107.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 119.16%. This contributed to the annual value of -$34.2 million for FY2024, which is 243.36% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Net Cash Flow stood at -$34.2 million for FY2024, which was down 243.36% from $23.9 million recorded in FY2023.
  • Whitehawk Therapeutics' Net Cash Flow's 5-year high stood at $144.5 million during FY2021, with a 5-year trough of -$109.9 million in FY2022.
  • Over the past 3 years, Whitehawk Therapeutics' median Net Cash Flow value was -$34.2 million (recorded in 2024), while the average stood at -$40.1 million.
  • Per our database at Business Quant, Whitehawk Therapeutics' Net Cash Flow soared by 1,353.98% in 2021 and then tumbled by 243.36% in 2024.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Net Cash Flow stood at -$11.5 million in 2020, then skyrocketed by 1,353.98% to $144.5 million in 2021, then tumbled by 176.04% to -$109.9 million in 2022, then soared by 121.72% to $23.9 million in 2023, then plummeted by 243.36% to -$34.2 million in 2024.